Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Burkitt Lymphoma 23Lymphoma, Large B-Cell, Diffuse 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Lymphoma, Follicular 12Lymphoma 11Rhabdomyosarcoma 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Biphenotypic, Acute 7Recurrence 6Lymphoma, Non-Hodgkin 6Lymphoma, B-Cell 6Wilms Tumor 5Sarcoma, Ewing 5Neuroblastoma 5Neoplasms 5Lymphoma, Mantle-Cell 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia 4Rhabdomyosarcoma, Embryonal 3Medulloblastoma 3Lymphoproliferative Disorders 3Lymphoma, T-Cell 3Down Syndrome 3Sarcoma 2Rhabdomyosarcoma, Alveolar 2Rhabdoid Tumor 2Plasmablastic Lymphoma 2Osteosarcoma 2

Interventions

prednylidene 1etoposide phosphate 1deltacortene 1Vincristine 1Vinblastine 1Specimen Handling 1Procarbazine 1Prednisone 1Prednisolone 1Nivolumab 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Etoposide 1Doxorubicin 1Dacarbazine 1Cyclophosphamide 1Brentuximab Vedotin 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 × Vincristine × 90 days × Clear all
NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡